FDG PET in the differential diagnosis of degenerative parkinsonian disorders: usefulness of voxel-based analysis in clinical practice

Annachiara Arnone1 · Michela Allocca1 · Rossella Di Dato1 · Giulia Puccini1 · Iashar Laghai2 · Federica Rubino1 · Matilde Nerattini1 · Silvia Ramati3 · Gemma Lombardi4 · Camilla Ferrari4 · Valentina Bessi4 · Sandro Sorbi4 · Maria Teresa De Cristofaro1 · Cristina Polito4 · Valentina Berti1

Received: 16 February 2022 / Accepted: 23 May 2022 / Published online: 14 June 2022
© The Author(s) 2022

Abstract

Background The early differential diagnosis among neurodegenerative parkinsonian disorders becomes essential to set up the correct clinical-therapeutic approach. The increased utilization of [18F] fluoro-deoxy-glucose positron emission tomography (FDG PET) and the pressure for cost-effectiveness request a systematic evaluation and a validation of its utility in clinical practice. This retrospective study aims to consider the contribution, in terms of increasing accuracy and increasing diagnostic confidence, of voxel-based FDG PET analyses in the differential diagnosis of these disorders, including Parkinson's disease, multiple system atrophy, progressive supranuclear palsy, and cortico-basal syndrome.

Method Eighty-three subjects with a clinically confirmed diagnosis of degenerative parkinsonian disorders who underwent FDG brain PET/CT were selected. A voxel-based analysis was set up using statistical parametric mapping (SPM) on MATLAB to produce maps of brain hypometabolism and relative hypermetabolism. Four nuclear physicians (two expert and two not expert), blinded to the patients’ symptoms, other physicians’ evaluations, and final clinical diagnosis, independently evaluated all data by visual assessment and by adopting metabolic maps.

Results In not-expert evaluators, the support of both hypometabolism and hypermetabolism maps results in a significant increase in diagnostic accuracy as well as clinical confidence. In expert evaluators, the increase in accuracy and in diagnostic confidence is mainly supported by hypometabolism maps alone.

Conclusions In this study, we demonstrated the additional value of combining voxel-based analyses with qualitative assessment of brain PET images. Moreover, maps of relative hypermetabolism can also make their contribution in clinical practice, particularly for less experienced evaluators.

Keywords Degenerative Parkinsonian disorders · SPM · Voxel-based analysis · Positron emission tomography · Metabolism maps · Differential diagnosis

Introduction

Atypical Parkinsonian disorders (APD) is a group of heterogeneous neurodegenerative diseases combining parkinsonian key features (bradykinesia, rigidity, and rest tremor) to dementia and to other clinical signs and symptoms related to the cortex or cerebellum [1]. Differently from Parkinson's disease (PD), these disorders are characterized not only by cell loss in the substantia nigra, but also by degeneration in added nervous system areas that normally contain dopamine receptors, known as the striatum, and usually do not respond well to drug treatment as levodopa [2]. The more severe evolution and prognosis require different therapeutic approaches. Therefore, the early differential diagnosis...
among APD, often complicated by overlapping clinical presentations, becomes essential to set up the correct clinical-therapeutic approach [3]. Brain imaging with positron emission tomography (PET) and \[^{18}\text{F}\]fluoro-deoxy-glucose (FDG) has been widely used in clinical practice as an important tool for revealing in vivo changes at different stages [4] and could represent a valid aid for the differential diagnosis of APD [5, 6]. In literature, many studies have described and considered frequent disease-related metabolic brain patterns. In PD, functional imaging has shown heterogeneous FDG PET patterns of hypometabolism, ranging from no cortical hypometabolism to diffuse parieto-temporo-occipital hypometabolism, which has been often associated with relative hypermetabolism of the striatal nuclei, globus pallidus, midbrain, thalamus, and cerebellum, as well as at the primary sensory-motor cortex [7, 8]. However, the origin of such pattern would be consistent across studies using global brain activity as a reference for activity scaling [9]. In Lewy Body Dementia (LBD), subcortical structures are relatively spared, as in PD. However, the reduction of cortical metabolic activity is widespread and more marked in occipital and temporo-parietal cortices, while a less relevant involvement is demonstrated in parietal and frontal cortices [10, 11]. On the other hand, in patients with progressive supranuclear palsy (PSP), a widespread cortical hypometabolism has been discovered, in particular in the frontal cortex, mainly in medial and premotor areas, as well as in subcortical structures, like the basal ganglia, especially caudate nucleus, and the midbrain [8, 12]. Concerning to multiple system atrophy (MSA), studies with FDG PET revealed significant hypometabolism in the striatum and in particular in the putamen, mainly in the parkinsonian form, as well as in the midbrain and cerebellum, prevalent in the cerebellar form [8, 12].

Notoriously, cortico-basal syndrome (CBS) is a very heterogeneous syndrome referring to gradual neurodegeneration in several cerebral cortical areas as well as deep structures, such as the basal ganglia. However, the underlying pathologies may be different, including CBD, AD, and others, which result in slightly different clinical phenotypes and in different FDG PET patterns [13]. In this context, FDG PET could also represent a valid tool to support the differential diagnosis within the possible etiologies underlying CBS. The typical pattern of hypometabolism of CBS due to CBD (CBS\textsubscript{CBD}) is characterized by an asymmetrical distribution, involving frontal, parietal, temporal cortical areas, basal ganglia and thalamus of the same hemisphere [8, 12, 14, 15].

With the evaluation of such metabolic patterns, FDG PET imaging has obtained an important role as supportive feature in the differential diagnosis of APD subtypes [16–19]. Moreover, some studies described the increase of diagnostic accuracy through the implementation of semiquantitative analysis, in support of qualitative evaluation [8, 20].

In the context of dementing neurodegenerative diseases, the European Association of Nuclear Medicine (EANM) and the European Academy of Neurology (EAN) have already recommended the use of semi-automated analyses as a valid helpful tool to improve the visual reading of FDG PET images [21]. However, both the increased utilization of FDG PET in APD disorders and the pressure for cost-effectiveness request a systematic evaluation and a validation of its utility in clinical practice. An optimized statistical parametric mapping (SPM) routine for FDG PET data analysis in single subjects has already been validated for the differential diagnosis of dementia [22]. Some authors have also evaluated its possible supportive role in a cohort of patients with APD, observing a significant impact on the clinical work-up and prognosis, particularly at early stages when the presentation is uncertain [1, 23]. However, to our knowledge, in literature, it has never been evaluated the impact of the use of FDG PET semi-automated analyses in a clinical setting, neither the use of both hypo- and hypermetabolism maps, as a way to detect both regions of decreased activity and of preserved neuronal activity, which could be especially useful in parkinsonian disorders. Therefore, the purpose of our study is to evaluate the contribution, in terms of increasing accuracy and increasing diagnostic confidence, of voxel-based FDG PET analyses in the differential diagnosis of neurodegenerative parkinsonian disorders, including PD, MSA, PSP, and CBS\textsubscript{CBD}. In particular, it will be evaluated the increasing accuracy and confidence of different nuclear medicine physicians in detecting the specific metabolic patterns after visual reading of FDG PET images, with the aid of statistical maps of hypometabolism and also of relative hypermetabolism.

Materials and methods

Subjects

Eighty-three subjects with a clinically confirmed diagnosis of neurodegenerative parkinsonian disorders (56 PD, 10 PSP, 9 MSA, 8 CBS\textsubscript{CBD}) who underwent FDG brain PET/CT in the period between January 2013 and December 2019 at the SOD of the Nuclear Medicine of AOU Careggi were selected. The confirmed clinical diagnosis has been made by neurologists after a period of at least 1 year, supported by FDG PET results (only qualitative assessment) but mainly based on symptoms evolution and response to treatments [24–31]. Due to the retrospective nature of the study, clinicians were not blinded with respect to FDG PET results.
PET acquisition and processing

PET scans were executed 30–40 min after \(^{18}\)F-FDG administration (3.7 MBq/kg) according to EANM guidelines for brain imaging. Images were obtained on a PET/CT scanner (Philips Gemini TF 16 PET/CT) and reconstructions were performed using 3D LOR iterative algorithm reconstruction (FOV: 256, matrix: 128 × 128, voxel dimensions: 2 × 2 × 2 mm). CT acquisition for attenuation correction was performed on spiral 16 slices CT with a slice thickness of 2 mm.

SPM analysis

A voxel-based analysis was set up using SPM12 on MATLAB (MathWorks Inc., Sherborn, MA, USA). Images were anonymized, manually reoriented, setting the origin to the anterior commissure, normalized according to the FDG template, and then smoothed (FWHM 8 mm) [32]. The control group has been provided by Neurological Study Group AIMN [33]. Comparisons between each patient and controls have been performed using independent samples T-test routine, with age as a nuisance variable and activity proportional scaling to the global mean value. The significance threshold was set at \(p < 0.001\), uncorrected for multiple comparisons. Only clusters containing more than 16 voxels were deemed to be significant. T-maps of both relative hypo- and hypermetabolism were visualized on the standardized T1-MRI provided by SPM. The performance of FDG PET qualitative assessment and SPM t-maps classification has been evaluated using multinomial logistic regression analysis. Cohen’s \(k\) coefficient was run to determine the agreement between readers.

Image evaluation

All images were independently evaluated by 4 nuclear physicians (2 experts and 2 not expert), blinded to the patients’ symptoms, other physicians’ evaluations, and final clinical diagnosis. Expert evaluators were defined as nuclear physicians with at least 5 years of experience in evaluating and reporting brain FDG PET examinations. Not-expert evaluators were physicians in specialty training in Nuclear Medicine, who were familiar with the type of examination, but with little experience in their work practice.

Each reader had to assign to each patient a specific degenerative parkinsonism pattern (among PD, MSA, PSP, CBS\(_{CBD}\)) and a confidence level (on a scale of 0 to 100).

Firstly, FDG PET qualitative assessment on a general color scale, usually adopted in clinical practice, was performed [12]. Then, the evaluators had to confirm or modify the diagnosis, indicating again the confidence level, based on the visualization of the hypometabolism maps. Finally, maps of relative hypermetabolism were also used to complete the whole evaluation. Hypo- and hypermetabolic T-maps of four patients are represented in Fig. 1.

Statistical analysis

Statistical analyses were performed using IBM® SPSS® Statistics, setting the significance threshold at \(p < 0.01\).

Results

Expert readers

The expert readers correctly classified 85.54% of the patients after qualitative assessment and 91.57% of the patients after the evaluation of the hypometabolism and hypermetabolism maps. The percentages of patients correctly classified after each assessment are shown in Table 1.

The percentage of patients correctly classified did not change for CBS, while significantly increased from 77.78 to 100% for MSA, from 92.86 to 96.43% for PD, and from 80 to 90% for PSP. In all cases, the percentage of correctly classified subjects did not increase after the evaluation of hypermetabolism maps. Diagnostic confidence values in general and by individual disease were reported in Table 2. Confidence in diagnosis after qualitative assessment and after evaluation of voxel-based maps is significantly increasing, overall and for each individual disease group. In general, diagnostic confidence increases from 80.6% by qualitative assessment to 87.11% with the help of hypometabolism maps and to 90.84% after assessment also of relative hypermetabolism maps. The values rise from 81.88 to 92.32% for PD; there is an increase from 81.11 to 90.56% for MSA; from 72.5 to 84.5% for PSP; finally, the increase is from 81.25 to 88.75% for CBS.

For Expert readers, sensitivity/specificity/PPV/NPV of a PD conclusion for PD diagnosis at qualitative assessment were respectively: 92.9%, 74.1%, 88.1%, and 88.1%; for MSA, 77.8%, 97.3%, 77.8%, and 77.8%, respectively; for PSP, 80%, 97.3%, 80%, and 80%, respectively; and for CBS, 50%, 98.7%, 80%, and 80%, respectively.

Sensitivity/specificity/PPV/NPV of a PD conclusion for PD diagnosis at hypo maps assessment were respectively: 96.4%, 85.2%, 93.1%, and 93.1%; for MSA, 100%, 97.3%, 81.8%, and 81.8%, respectively; for PSP, 90%, 100%, 100%, and 100%, respectively; and for CBS, 50%, 98.7%, 80%, and 80%, respectively.

Sensitivity/specificity/PPV/NPV of a PD conclusion for PD diagnosis at hyper maps assessment were respectively: 96.4%, 85.2%, 93.1%, and 93.1%; for MSA, 100%, 97.3%, 81.8%, and 81.8%, respectively; for PSP, 90%, 100%, 100%, and 100%, respectively; and for CBS, 50%, 98.7%, 80%, and 80%, respectively.
Fig. 1 Hypo- and hypermetabolic T-maps of four patients, one for each disease in the differential diagnosis. PD (a–b), MSA (c–d), PSP (e–f), and CBSCBD (g–h), respectively.
100%, and 100%, respectively; and for CBS, 50%, 98.7%, 80%, and 80%, respectively.

**Not-expert readers**

Not-expert readers correctly classified 61.45% of patients after qualitative assessment, 74.7% after the help of the hypometabolism maps, and 81.93% after also assessing the relative hypermetabolism maps. Accuracy values for individual pathology and overall accuracy results are shown in Table 3. The diagnostic accuracy did not change for CBS. It increased from 66.67 to 88.89% for MSA. The percentage of correctly classified subjects increased progressively from 62.50 to 85.71% for PD and from 60 to 80% for PSP.

The overall and single pathology diagnostic confidence values were reported in Table 4. Confidence in correct diagnosis after qualitative assessment and after evaluation of hypometabolism maps shows a statistically significant increase, both overall and by single pathology ($p < 0.01$). Such classification resulted in statistically significant in predicting follow-up clinical diagnosis at multinomial logistic regression analysis ($p < 0.001$).

For non-expert readers, sensitivity/specificity/PPV/NPV of a PD conclusion for PD diagnosis at hypometabolism maps assessment was respectively 76.8%, 81.2%, 89.6%, and 89.6%, respectively; for MSA, 88.9%, 92.3%, and 92.3%, respectively; for PSP, 70%, 91.8%, 53.8%, and 53.8%, respectively; and for CBS, 50%, 97.3%, and 66.7%, respectively.

Sensitivity/specificity/PPV/NPV of a PD conclusion for PD diagnosis at hypermetabolism maps assessment was respectively 85.7%, 85.2%, 92.3%, and 92.3%; for MSA, 88.9%, 90.5%, 53.3%, and 53.3%, respectively; for PSP, 80%, 97.3%, 80%, and 80%, respectively; and for CBS, 50%, 97.3%, 66.7%, and 66.7%, respectively.

Results have been graphically summarized in Fig. 2. Between both expert and non-expert readers, Cohen’s $k$ coefficient stated agreement regarding qualitative, hypometabolic, and hypermetabolic maps ($k = 0.397$, $k = 0.627$, $k = 0.746$, respectively, $p < 0.001$) (Fig. 2).

**Discussion**

Our study takes part in the well-known debate about the utility of metabolic biomarkers in the diagnostic work-up of APD, in order to obtain benefits for treatment options and support to the patients [1, 23]. In particular, we aim to underline the clinical practice role of FDG PET/CT imaging in the differential diagnosis among neurodegenerative parkinsonian disorders. Our specific focus was to evaluate the additional value, over qualitative PET images assessment, of not only maps of hypometabolism, as a mean to evaluate regions of neuronal dysfunction and loss, but also maps

| Table 1 Accuracy values obtained by expert readers’ evaluation | Table 2 Diagnostic confidence values obtained by expert readers’ evaluation |
|---------------------------------------------------------------|--------------------------------------------------------------------------|
| Qualitative assessment | Additional hypometabolism maps assessment | Additional hypermetabolism maps assessment |
| PD | 92.86 | 96.43 |
| MSA | 77.78 | 100 |
| PSP | 80 | 90 |
| CBS | 50 | 50 |
| %cc total | 85.54 | 91.57 |

| Diagnostic confidence (0–100) | Qualitative evaluation | Additional hypometabolism maps assessment | Additional hypermetabolism maps assessment |
|-------------------------------|------------------------|----------------------------------------|------------------------------------------|
| Mean | 80.60 | 87.11 | 90.84 |
| Mean PD | 81.88 | 87.68 | 92.32 |
| Mean MSA | 81.11 | 88.89 | 90.56 |
| Mean PSP | 72.50 | 81.50 | 84.50 |
| Mean CBS | 81.25 | 88.13 | 88.75 |
of relative hypermetabolism, as a way to evaluate cerebral regions of preserved synaptic activity.

Several studies in the literature have demonstrated the significant value of voxel-based analyses as an aid in brain FDG PET assessment in patients with cognitive decline [16–19, 21, 22]. Similar results are also expected in the field of APD, although there are no studies that have ever formalized this result. First of all, the results of our study show that the diagnostic accuracy values are higher in expert evaluators than in not-experts, especially regarding the qualitative assessment of PET images. This result was obviously expected and it emphasizes the complexity of brain FDG PET evaluation, which requires considerable work experience. For expert evaluators, overall high accuracy just after qualitative assessment increases with the use of hypometabolism maps and concurrent increase also in confidence levels and reaches stability after the use of hypermetabolism maps. It suggests that they could not be completely useless in this group of evaluators. For not-expert readers, overall accuracy after qualitative assessment is suboptimal and the use of both hypometabolism and hypermetabolism maps let them arrive at levels of accuracy similar to expert readers, consequently increasing their levels of confidence.

| Diagnostic confidence (0–100) | Qualitative evaluation | Additional hypometabolism maps assessment | Additional hypermetabolism maps assessment |
|-------------------------------|------------------------|------------------------------------------|------------------------------------------|
| Mean                          | 77.71                  | 83.73                                    | 88.31                                    |
| Mean PD                       | 78.04                  | 82.68                                    | 88.57                                    |
| Mean MSA                      | 85.56                  | 94.44                                    | 95.56                                    |
| Mean PSP                      | 69                     | 79                                       | 80                                       |
| Mean CBS                      | 77.50                  | 85                                       | 88.75                                    |

**Fig. 2** Graphics summarizing the estimation in terms of percentage of correctly classified patients and the confidence level respectively by experts (**a**–**b**) and not experts (**c**–**d**). Colors were set in order to highlight the added value of hypometabolism and hypermetabolism maps compared to the qualitative assessment alone, as indicated in the legend.
Regarding the different diseases considered in this study, we could express the following considerations.

In the cases of PD disease, experts reach the highest accuracy, suggesting that this pattern is well recognizable even if very heterogeneous actually including both forms of PD patients, either without cognitive deficits or with mild cognitive impairment, ranging from no cortical hypometabolism to some areas of posterior hypometabolism. Accuracy levels still improve after the use of hypometabolism maps but do not change after the use of hypermetabolism maps, suggesting that the typical relative hypermetabolism in striata is well recognizable by the experts. Instead, not experts’ accuracy is quite low after qualitative assessment, suggesting that the widespread hypometabolism is difficult to recognize by them. However, with the use of both hypometabolism and hypermetabolism maps, accuracy increases of around 10% each time, reaching good levels, suggesting that voxel-based assessment is fundamental for not-expert readers. However, they did not reach the levels of accuracy of experts. Regarding confidence, it is quite high and in both groups increases at each evaluation step. In the cases of MSA disease, accuracy after the qualitative assessment is one of the lowest for the experts; however, it reaches 100% after the use of hypometabolism maps. This suggests that hypometabolism maps are really relevant even in experts’ readers to identify the MSA patterns. In not experts, it happens almost the same thing. After hypometabolism maps, they reached the highest accuracy among diseases, and it did not improve after hypermetabolism maps. In both groups, however, the use of hypermetabolism maps increases confidence, maybe because of the confirmation that there is a metabolic sparing of cortical regions [24, 25]. In the cases of PSP disease, one of the lowest accuracy levels after qualitative assessment happens in both experts and not experts, improving after hypometabolism maps in both groups and after hypermetabolism maps only in not experts. This could suggest the difficulty in evaluating this pathology, which could present with different patterns in the different variants [26]. This lower accuracy level as compared to the other pathologies is reflected by the confidence, which is the lowest among pathologies. In the cases of CBS disease, diagnostic accuracy values are rather low in both expert and not-expert readers. This is in line with the literature since the typical CBS-specific metabolic pattern is actually present only in the subgroup of patients with cortico-basal degeneration (CBD) pathology, while others could show metabolic patterns mimicking other diseases [13, 27]. It also seems that when the specific pattern is present (cortical and subcortical hypometabolism with frank asymmetry), it is well recognizable even only with qualitative assessment, and even by not-expert evaluators, since the percentages of correctly classified subjects did not improve after the use of any statistical maps. For expert evaluators, it can be noted an increase in accuracy only with the help of the hypometabolism maps, while it remains at the same level after the evaluation of the relative hypermetabolism maps. This result suggests that expert readers probably are able to evaluate which regions are spared by disease already from the qualitative assessment, and do not need further analysis. Moreover, the accuracy and the confidence values increase significantly with the help of the hypometabolism maps, so we derived that experts find valuable help in this type of analysis. On the other hand, even if relative hypermetabolism maps did not increase accuracy values for experts, diagnostic confidence seems to grow up. It can be deduced that this type of analysis is not completely useless, but contributes to increase the certainty with which the diagnosis is proposed. With regard to not-expert evaluators, the use of both hypo- and hypermetabolism maps proves to be very useful. In fact these evaluators, starting from rather low levels of accuracy at qualitative assessment alone, reaches much better levels, not equal to those of the experts but however very close to them and clinically acceptable. It is inferred that the not-expert evaluators need to make use of further analysis to better understand where both the disease-affected and disease-spared regions are located. It is also interesting to notice that the diagnostic confidence in such evaluations increases significantly as accuracy increases.

Conclusions

Early diagnosis of neurodegenerative parkinsonian disorders is a crucial point of interest because both prognosis in terms of disease duration and clinical progression, and treatment options can vary considerably among the various subtypes. In this study, we demonstrated the additional value of combining voxel-based analyses with a qualitative assessment of brain PET images. It is shown that metabolic maps are very useful in supporting this type of evaluation, especially for less experienced nuclear physicians, but also for experienced ones. In not-expert evaluators, the support results in a significant increase in diagnostic accuracy as well as clinical confidence. In expert evaluators, the increase in accuracy is supported by hypometabolism maps alone, and there is still an increase in diagnostic confidence. Finally, in this particular group of diseases, it was shown that even maps of relative hypermetabolism can make their contribution to clinical practice, particularly for less experienced evaluators.

Funding Open access funding provided by Università degli Studi di Firenze within the CRUI-CARE Agreement.

Declarations

Ethical approval None.
Conflict of interest The authors declare no competing interests.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

References

1. Caminiti SP, Alongi P, Majorino MA, Cerami C, Gianolli L, Comi G, Perani D (2017) Evaluation of an optimized [18F] fluoro-deoxy-glucose positron emission tomography voxel-wise method to early support differential diagnosis in atypical Parkinsonian disorders. Eur J Nucl Neurol 24(5):687–e26. https://doi.org/10.1111/eje.13269

2. Postuma RB, Berg D, Stern M, Poewe W, Olanow CW, Oertel W, Obeso J, Marek K, Litvan I, Lang AE, Halliday G, Goetz CG, Gasser T, Dubois B, Chan P, Bloem BR, Adler CH, Deuschl G (2015) MDS clinical diagnostic criteria for Parkinson’s disease. Mov Disord 30(12):1591–1601. https://doi.org/10.1002/mds.26424

3. Reich SG, Savitt JM (2019) Parkinson’s disease. Med Clin North Am 103(2):337–350. https://doi.org/10.1016/j.mcna.2018.10.014

4. Berti V, Pupi A, Mosconi L (2011) PET/CT in diagnosis of movement disorders. Mov Disord 26(3):912–921. https://doi.org/10.1002/mds.25361

5. Walker Z, Gandolfo F, Orini S, Garibotto V, Agosta F, Arbizu J, arnoldi P, Drzezga A, Nestor P, Boccardi M, Altomare D, Fesl C, Dodich A, Iannaccone S, Magnani G, Marcone A, Guglielmelli P, Vanoli G, Cappa SF, Perani D (2010) FDG-PET in the differential diagnosis of corticobasal degeneration and parkinsonism: a metabolic imaging study using pattern analysis. Lancet Neurol 9(2):149–158. https://doi.org/10.1016/S1474-4422(10)70002-8

6. Perani D, Delia Rosa PA, Cerami C et al (2014) Validation of an optimized SPM procedure for FDG-PET in dementia diagnosis in a clinical setting. Neuroimage Clin 3:445–454

7. Meyer PT, Frings L, Rücker G, Hellwig S (2017) 18F-FDG PET in Parkinsonism: differential diagnosis and evaluation of cognitive impairment. J Nucl Med 58(12):1888–1898. https://doi.org/10.2967/jnumed.116.186403

8. Lee MJ, Kim TH, Mun CW, Shin HK, Son J, Lee JH (2018) Spatial correlation and segregation of multimodal MRI abnormalities in multiple system atrophy. J Neurol 265(7):1540–1547. https://doi.org/10.1007/s00415-018-8874-z

9. Bozghi A, Khachatrian M, Jonsdottir KY, Sato N, Matsuda H, Ito K, Arahata Y, Kato T, Gjedde A (2013) Cortical hypometabolism and hypoperfusion in Parkinson’s disease is extensive: probably even at early disease stages. Brain Struct Funct 214(4):303–17. https://doi.org/10.1007/s00429-010-0246-0

10. Berti V, Pupi A, Mosconi L (2011) PET-CT in diagnosis of dementia.pdf. Ann N Y Acad Sci 1228:81–92. https://doi.org/10.1111/j.1749-6632.2011.06015.x

11. Yong SW, Yoon JK, An YS, Lee PH (2007) A comparison of cerebral glucose metabolism in Parkinson’s disease, Parkinson’s disease dementia and dementia with Lewy bodies. Eur J Neurol 14(12):1357–1362. https://doi.org/10.1111/j.1468-1331.2007.01977.x

12. Berti V, Pupi A, Mosconi L (2011) PET / CT in diagnosis of movement disorders Edited by Foxit Reader. Ann N Y Acad Sci 1228(C):93–108. https://doi.org/10.1111/j.1749-6632.2011.06025.x

13. Pardini M, Huey ED, Spinu S, Kreisl WC, Morbelli S, Wassermann EM, Nobili F, Ghatti B, Grafman J (2019) FDG-PET patterns associated with underlying pathology in corticobasal syndrome. Neurology 92(10):e1211–e13. https://doi.org/10.1212/WNL.0000000000007038

14. Klaffke S, Kuhn AA, Plotkin M, Amthauer H, Harnack D, Felix R, Kupsch A (2006) Dopamine transporters, D2 receptors, and glucose metabolism in corticobasal degeneration. Mov Disord 21(10):1724–7. https://doi.org/10.1002/mds.21004

15. Juh R, Pae CU, Kim TS, Lee CU, Choe B, Suh T (2005) Cerebral glucose metabolism in corticobasal degeneration comparison with progressive supranuclear palsy using statistical mapping analysis. Neurosni Lett 383(1–2):22–7. https://doi.org/10.1016/j.neulet.2005.03.057

16. McKeith IG, Dickson DW, Lowe J et al (2005) Diagnosis and management of dementia with Lewy bodies: third report of the DLB Consortium. Neurology 65(1863–1872):16

17. Gilman S, Wenning GK, Low PA et al (2008) Second consensus statement on the diagnosis of multiple system atrophy. Neurology 71(670–676):17

18. Armstrong MJ, Litvan I, Lang AE et al (2013) Criteria for the diagnosis of corticobasal degeneration. Neurology 80:496–503

19. Tripathi M, Dhawan V, Peng S et al (2013) Differential diagnosis of parkinsonism syndromes using F-18 fluoro-deoxy-glucose positron emission tomography. Neuroendocrinology 55:483–492

20. Tang CC, Poston KL, Eckert T, Feigin A, Frucht S, Gudesblatt M, Dhawan V, Lesser M, Vonsattel JP, Fahn S, Eidelberg D (2010) Differential diagnosis of parkinsonism: a metabolic imaging study using pattern analysis. Lancet Neurol 9(2):149–158. https://doi.org/10.1016/S1474-4422(10)70002-8

21. Guedj E et al (2022) EANM procedure guidelines for brain PET imaging using [18F]FDG, version 3. Eur J Nucl Med Mol Imaging. 49(2):632–651

22. Perani D, Della Rosa PA, Cerami C et al (2014) Validation of an optimized SPM procedure for FDG-PET in dementia diagnosis in a clinical setting. Neuroimage Clin 3:445–454

23. Meyer PT, Frings L, Rücker G, Hellwig S (2017) 18F-FDG PET in Parkinsonism: differential diagnosis and evaluation of cognitive impairment. J Nucl Med 58(12):1888–1898. https://doi.org/10.2967/jnumed.116.186403

24. Lee MJ, Kim TH, Mun CW, Shin HK, Son J, Lee JH (2018) Spatial correlation and segregation of multimodal MRI abnormalities in multiple system atrophy. Mov Disord 28(3):362–369. https://doi.org/10.1002/mds.25314

25. Lee MJ, Kim TH, Mun CW, Shin HK, Son J, Lee JH (2018) Spatial correlation and segregation of multimodal MRI abnormalities in multiple system atrophy. J Neurol 265(7):1540–1547. https://doi.org/10.1007/S00415-018-8874-z

26. Armstrong MJ (2018) Progressive supranuclear palsy: an update. Curr Neurol Neurosci Rep 18(3):1–9. https://doi.org/10.1007/s11910-018-0819-5

27. Cerami C, Dodich A, Iamacone S, Magnani G, Marcone A, Guglielmelli P, Vanoli G, Cappa SF, Perani D (2020) Individual brain metabolic signatures in corticobasal syndrome. J Alzheimers Dis 76(2):517–528. https://doi.org/10.3233/JAD-200153

28. Watanabe H, Hara K, Ito M, Katsuno M, Sobue G (2018) New diagnostic criteria for Parkinson’s disease: MDS-PD criteria. Brain Nerve 70(2):139–146. https://doi.org/10.11477/mf.1416200966 (Japanese)

29. Alexander SK, Rittman T, Xuereb JH, Bak TH, Hodges JR, Rowe JB (2014) Validation of the new consensus criteria for the
diagnosis of corticobasal degeneration. J Neurol Neurosurg Psychiatry 85(8):925–9. https://doi.org/10.1136/jnnp-2013-307035

30. Gilman S, Wenning GK, Low PA, Brooks DJ, Mathias CJ, Trojanowski JQ, Wood NW, Colosimo C, Dürr A, Fowler CJ, Kaufmann H, Klockgether T, Lees A, Poewe W, Quinn N, Revesz T, Robertson D, Sandroni P, Seppi K, Vidailhet M (2008) Second consensus statement on the diagnosis of multiple system atrophy. Neurology 71(9):670–6. https://doi.org/10.1212/01.wnl.0000324625.00404.15

31. Höglinger GU, Respondek G, Stamelou M, Kurz C, Josephs KA, Lang AE, Mollenhauer B, Müller U, Nilsson C, Whitwell JL, Arzberger T, Englund E, Gelpi E, Giese A, Irwin DJ, Meissner WG, PANTELYAT A, Rajput A, van Swieten JC, Troakes C, Antonini A, Bhatia KP, Bordelon Y, Compta Y, Corvol JC, Colosimo C, Dickson DW, Dodel R, Fugan L, Grossman M, Kassubeck J, Krismer F, Lev J, Lorenz L, Morris HR, Nestor P, Oertel WH, Poewe W, Rabinovici G, Rowe JB, Schellenberg GD, Seppi K, van Eimeren T, Wenning GK, Boxer AL, Golbi LI, Litvan I (2017) Movement Disorder Society-Endorsed PSP Study Group Clinical diagnosis of progressive supranuclear palsy: the movement disorder society criteria. Mov Disord 32(6):853–864. https://doi.org/10.1002/mds.26987

32. Della Rosa PA, Cerami C, Gallivanone F, Prestia A, Caroli A, Castiglioni I, Gilardi MC, Frisoni G, Friston K, Ashburner J, Perani D, EADC-PET Consortium (2014) A standardized [18F]-FDG-PET template for spatial normalization in statistical parametric mapping of dementia. Neuroinformatics 12(4):575–93. https://doi.org/10.1007/s12021-014-9235-4

33. Caminiti SP, Sala A, Presotto L, Chincarini A, Sestini S, Perani D; Alzheimer’s Disease Neuroimaging Initiative (ADNI), for the Associazione Italiana Medicina Nucleare (AIMN) datasets, The AIMN Neurology Study-Group collaborators; Schillaci O, Berti V, Calcagni ML, Cistaro A, Morbelli S, Nobili F, Pappatà S, Votterani D, Gobbo CL (2021) Validation of FDG-PET datasets of normal controls for the extraction of SPM-based brain metabolism maps. Eur J Nucl Med Mol Imaging. 48(8):2486-2499https://doi.org/10.1007/s00259-020-05175-1

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.